Day One Biopharmaceuticals, Inc.

NasdaqGS DAWN

Day One Biopharmaceuticals, Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2024: USD 99.82 M

Day One Biopharmaceuticals, Inc. Gross Profit is USD 99.82 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 21,800.00% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.

Day One Biopharmaceuticals, Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -460.00 K, a -178.79% change year over year.
Day One Biopharmaceuticals, Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -165.00 K, a 0.00% change year over year.
Day One Biopharmaceuticals, Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 0.00.

Key data

Date	Gross Profit	Operating Income	EBIT	EBITDA

NasdaqGS: DAWN

Day One Biopharmaceuticals, Inc.

CEO	Dr. Jeremy Bender M.B.A., Ph.D.
IPO Date	May 27, 2021
Location	United States
Headquarters	395 Oyster Point Boulevard
Employees	174
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Key trends

Past 5 years